Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration: 3-Year Buprenorphine Retention in OUD
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Buprenorphine has become the major treatment for opioid use disorder (OUD) but data on long treatment term retention and its correlates are sparse. METHODS: All veterans with OUD treated in Veterans Health Administration (VHA) facilities nationally in fiscal year (FY) 2012, and who began treatment with buprenorphine as indicated by a first prescription after the first 60 days of the year were identified with the date of and their last prescription from FY 2012-2015. Veterans were classified into four groups based on time from first to last prescription: (0-30 days, 31-365 days; 1-3 years; and more than 3 years). These groups were compared on socio-demographic, diagnoses and service, and psychotropic drug use. Kaplan-Meier curves and Cox proportional hazards models were used to identify variables independently associated with retention in buprenorphine treatment. RESULTS: Veterans newly started on buprenorphine (n = 3,151) were retained in treatment for a mean duration of 1.68 years (standard deviation [SD] 1.23), with 61.60% (n = 1,941) retained for more than a year and 31.83% (n = 1,003) for more than 3 years. Cox proportion hazards model showed that only black race (Hazards ratio [HR] 1.26; standard error [SE] .06; p.0003), the Charlson index (HR 1.03; SE .01; p.0132) and emergency room visits during FY 2012 (HR 1.03; SE .01; p < .0001) were the only available variables independently associated higher odds of buprenorphine discontinuation. CONCLUSIONS: Buprenorphine retention was substantial among veterans treated in VHA, but few individual characteristics correlated with retention. SCIENTIFIC SIGNIFICANCE: Future research focused on identifying further correlates of treatment retention is required to help devise interventions to improve treatment continuation. (Am J Addict 2017;26:572-580).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An effect size primer: A guide for clinicians and researchers.
Ferguson, C. J. (2009) · Professional Psychology: Research and Practice · doi:10.1037/a0015808 · Cited by 3,467 · cited 1×
“20 were considered to represent more than small differences.(25) Variables were included only if the base rate was more than 5%.”
BackgroundNational and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Effective Medical Treatment of Opiate Addiction
Addiction, N. C. D. P. O. E. M. T. O. O. (1998) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.280.22.1936 · Cited by 577
Maintenance Medication for Opiate Addiction: The Foundation of Recovery
Bart, G. (2012) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.694598 · Cited by 461 · cited 2×
“Buprenorphine has thus evolved as the favored choice for OAT among both patients and physicians, but there is sparse data regarding the long term retention in buprenorphine treatment for OUD.(16) A recent literature Received October 6, 2016; revised February 7, 2017; accepted March 27, 2017.”
BackgroundA Controlled Trial Comparing Buprenorphine and Methadone Maintenance in Opioid Dependence
Ling, W. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050035005 · Cited by 366 · cited 1×
“In prior reports from clinical trials data, buprenorphine treatment retention varied from 20% at 52 weeks to 53% at 1 year and 25% at 2 years in more recent studies.(26,27) One-year retention rates reported from naturalistic studies are generally lower than in the VHA sample reported here, with 32–57% in small practic…”
BackgroundAlford, D. P., LaBelle, C. T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.541 · Cited by 267
Cited by
Retention of patients in opioid substitution treatment: A systematic review
O’Connor, A. M., Cousins, G., Durand, L., Barry, J., & Boland, F. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232086 · Cited by 298
Samples, H., Williams, A. R., Olfson, M., & Crystal, S. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.09.001 · Cited by 235
“However, results vary in the direction and magnitude of risk attributable to each characteristic (Manhapra et al., 2017; Saloner et al., 2017; Weinstein et al., 2017).”
BackgroundLin, L. A., Bohnert, A. S. B., Blow, F. C., Gordon, A. J., Ignacio, R. V., Kim, H. M., & Ilgen, M. A. (2021) · Addiction · doi:10.1111/add.15116 · Cited by 108
Lopian, K. M., Chebolu, E., Kulak, J. A., Kahn, L. S., & Blondell, R. D. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.11.002 · Cited by 16
Metadata
- Authors
- Manhapra, A., Petrakis, I., & Rosenheck, R.
- Venue
- The American Journal on Addictions
- Publisher
- Wiley
- Published
- 2017-05-04
- Volume
- 26
- Issue
- 6
- Pages
- 572-580
- ISSN
- 1055-0496 (ISSN-L)
- OpenAlex
- W2610572186
- Cited by
- 92
- References
- 6
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration: 3-Year Buprenorphine Retention in OUD. https://app.cochat.ai/papers/10.1111/ajad.12553
- The paper
- Manhapra, A., Petrakis, I., & Rosenheck, R. (2017). Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration: 3-Year Buprenorphine Retention in OUD. The American Journal on Addictions. https://doi.org/10.1111/ajad.12553
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.